NLRP3 and myeloid sarcoma: In other work, chronic oral administration of the NLRP3 inhibitor, MCC950 in a relapsing–remitting EAE mouse model of MS-associated neuropathic pain progressively reversed neuropathic pain behaviour, further implicating a pathobiological role for NLRP3 inflammasome activation in MS-associated neuropathic pain (Khan et al. 2018).